NCT05844592View on ClinicalTrials.gov

First in Human, Single Ascending Dose Study

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 21, 2022

Primary Completion Date

July 16, 2022

Study Completion Date

August 31, 2022

Conditions
Ulcerative Colitis
Interventions
DRUG

INV-101

subjects will be randomized 3:1 ratio

Trial Locations (1)

Unknown

Innovo Therapeutics, Inc., Seoul

Sponsors
All Listed Sponsors
lead

Innovo Therapeutics, Inc.

INDUSTRY

NCT05844592 - First in Human, Single Ascending Dose Study | Biotech Hunter | Biotech Hunter